Nasdaq · CIK 0001681682
NDRA ENDRA Life Sciences Inc.
Insider trading from SEC Form 4. Last filing Mar 4, 2026.
In brief
ENDRA Life Sciences Inc. (NDRA) has 11 SEC Form 4 filings on file from 5 insiders, the latest filed on Mar 4, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
1 Form 144 notice of planned sales is on file, the latest filed Jun 25, 2026.
Last 90 days
Signals
Open-market buys and sells at ENDRA Life Sciences Inc., scored.
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 25, 2026 | Anthony DiGiandomenico Board Member | 70,822 5.23% of outstanding | $425k | Jun 26, 2026 | none |
Transactions
Every row filed, 12 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | Richard Jacroux Chief Financial Officer | AGrant or award Common Stock | +13,461 | $0.00 | $0 | 33,461 | Mar 4, 2026 |
| Mar 2, 2026 | Alexander Y Tokman Chief Executive Officer | AGrant or award Common Stock | +26,921 | $0.00 | $0 | 101,926 | Mar 4, 2026 |
| Jan 21, 2026 | Lou Basenese director | AGrant or award Common Stock | +60,324 | $0.00 | $0 | 65,709 | Jan 23, 2026 |
| Jan 21, 2026 | Anthony Digiandomenico director | AGrant or award Common Stock | +60,324 | $0.00 | $0 | 136,589 | Jan 23, 2026 |
| Jan 21, 2026 | Alexander Y Tokman Chief Executive Officer | AGrant or award Common Stock | +75,000 | $0.00 | $0 | 75,005 | Jan 23, 2026 |
| Jan 21, 2026 | Richard Jacroux Chief Financial Officer | AGrant or award Common Stock | +20,000 | $0.00 | $0 | 20,000 | Jan 23, 2026 |
| Jan 21, 2026 | Michael Harsh director | AGrant or award Common Stock | +60,324 | $0.00 | $0 | 65,710 | Jan 23, 2026 |
| Oct 10, 2025 | Anthony Digiandomenico director | AGrant or award Common Stock | +70,822 | $7.06 | $500k | 76,265 | Oct 15, 2025 |
| Oct 10, 2025 | Anthony Digiandomenico director | AGrant or award Warrantsderivative | +141,644 | $7.06 | $1.0M | 141,644 | Oct 15, 2025 |
| Jun 11, 2025 | Lou Basenese director | AGrant or award Common Stock | +5,384 | $0.00 | $0 | 5,385 | Jul 1, 2025 |
| Jun 11, 2025 | Anthony Digiandomenico director | AGrant or award Common Stock | +5,384 | $0.00 | $0 | 5,443 | Jul 1, 2025 |
| Jun 11, 2025 | Michael Harsh director | AGrant or award Common Stock | +5,384 | $0.00 | $0 | 5,386 | Jul 1, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Lou Basenesedirector
- Anthony Digiandomenicoofficer, director, owner
- Michael Harshdirector
- Richard JacrouxChief Financial Officer
- Alexander Y TokmanChief Executive Officer
Questions about NDRA
Answered from the filings on this page, as of the latest one.
Are insiders buying NDRA?
No. In the last 90 days no insider at ENDRA Life Sciences Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade NDRA on the open market?
No open-market trade has been scored at ENDRA Life Sciences Inc.. The latest Form 4 on file was filed on Mar 4, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at ENDRA Life Sciences Inc.?
5 people have filed a Form 4 at ENDRA Life Sciences Inc., among them Lou Basenese (director), Anthony Digiandomenico (officer, director and 10% owner), Michael Harsh (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.